Your session is about to expire
← Back to Search
JNJ-18038683 for Bipolar Disorder
Study Summary
This trial will study JNJ-18038683 to see if it helps with cognitive deficits and residual depressive symptoms in bipolar patients who are already receiving treatment for depression.
- Bipolar Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 60 Patients • NCT02466685Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For whom does this study hold the most potential?
"This clinical trial is seeking 60 individuals with a history of manic disorder who are between 18-60 years old. The ideal candidate will meet the following requirements:- Receiving a single mood stabilizer (e.g., lithium, valproate, or lamictal) for at least 2 months with a stable dose- Medically stable enough to complete an 8-week clinical trial, as judged by the investigator- Negative pregnancy serum and urine test at screening and baseline, respectively. Willing to use adequate protection (i.e. double barrier method) for birth control- Taking antidepressants, mood stabil"
What are the harmful effects that JNJ-18038683 might have on patients?
"JNJ-18038683's safety is estimated to be a 2. This is because, while there is some data supporting safety, there is none for efficacy."
Would this study be appropriate for elderly patients?
"According to the requirements for this clinical trial, patients must be aged 18 to 60. For context, there are 204 studies for people under the age of 18 and 931 for patients over 65."
Can new volunteers still join this research project?
"Data from clinicaltrials.gov suggests that this particular medical trial is not actively recruiting patients at the moment. Although, there are 1279 other trials that are recruiting patients."
Share this study with friends
Copy Link
Messenger